Free Access
Editorial
Issue
Oncol.
Volume 18, Number 9-10, Septembre-Octobre 2016
Immunothérapie
Page(s) 499 - 500
Section Éditorial / Editorial
DOI https://doi.org/10.1007/s10269-016-2666-9
Published online 10 November 2016
  • Vozy A, Coutzac C (2016) Colite induite par les inhibiteurs de checkpoint immunitaire : anticorps anti-CTLA-4 et anticorps anti-PD-1/PDL-1. Oncologie 18:501–8 [CrossRef] [lavoisier] [Google Scholar]
  • Dubin K, Callahan MK, Ren B, et al (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7:10391 [Google Scholar]
  • Lambert T, Doucet L (2016) Immunothérapie et dysfonctions thyroïdiennes : mise au point sur les connaissances actuelles. Oncologie 18:509–15 [CrossRef] [lavoisier] [Google Scholar]
  • Hodi FS, O'Day SJ, McDermott DF, et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–23 [CrossRef] [PubMed] [Google Scholar]
  • Robert C, Thomas L, Bondarenko I, et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–26 [Google Scholar]
  • Colle E, Andre T, Lebbe C, Borg C (2016) Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1). Oncologie 18:533–42 [CrossRef] [lavoisier] [Google Scholar]
  • Herbst RS, Soria JC, Kowanetz M, et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–7 [CrossRef] [PubMed] [Google Scholar]
  • Loir E, Jouinot A (2016) Immunothérapie et évaluation de la réponse tumorale : la difficulté de la pseudoprogression. Oncologie 18:523–6 [CrossRef] [lavoisier] [Google Scholar]
  • Wolchok JD, Hoos A, O'Day S, et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–20 [CrossRef] [PubMed] [Google Scholar]
  • Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541–3 [CrossRef] [PubMed] [Google Scholar]
  • Gougis P, Teixeira L (2016) Les virus oncolytiques, première validation pour une classe thérapeutique pas si nouvelle. Oncologie 18:517–22 [CrossRef] [lavoisier] [Google Scholar]
  • Andtbacka RHI, Kaufman HL, Collichio F, et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780–8 [CrossRef] [PubMed] [Google Scholar]
  • Tiako Meyo M, Huillard O, Alexandre J (2016) Immunothérapie en onco-urologie. Oncologie 18:527–32 [CrossRef] [lavoisier] [Google Scholar]
  • Kwon ED, Drake CG, Scher HI, et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:700–12 [CrossRef] [PubMed] [Google Scholar]
  • Fankhauser CD, Curioni-Fontecedro A, Allmann V, et al (2015) Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer 113:411–3 [CrossRef] [PubMed] [Google Scholar]
  • Verret B, Loirat D (2016) Immunothérapie et cancer du sein. Oncologie 18:551–8 [CrossRef] [lavoisier] [Google Scholar]
  • Adams S, Gray RJ, Demaria S, et al (2014) Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959–66 [CrossRef] [PubMed] [Google Scholar]
  • Gervais C, Scotté F (2016) Les cancers des voies aériennes et digestives supérieures à l'ère de l'immunothérapie : rationnels et spécificités de prise en charge. Oncologie 18:543–50 [CrossRef] [lavoisier] [Google Scholar]
  • Ferris RL, Blumenschein GR, Fayette J, et al (2016) Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141 — ASCO. J Clin Oncol 34 (suppl; abstr 6009) [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.